Skip to main content

Sarcoidosis

2
Pipeline Programs
7
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Gilead Sciences
LETAIRISApproved
ambrisentan
Gilead Sciences
Endothelin Receptor Antagonist [EPC]oral2007
89M Part D

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
1
AmbrisentanPHASE_2_3
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
AmbrisentanPhase 2/31 trial
Active Trials
NCT00851929Completed16Est. Nov 2011
Enterprise Therapeutics
1 program
19 gauge needleN/A1 trial
Active Trials
NCT04770948Completed150Est. Sep 2023
Apollo Therapeutics
Apollo TherapeuticsUK - Cambridge
1 program
19G EBUS-TBNA NeedleN/A
Cook Medical
Cook MedicalIN - Bloomington
1 program
EndosonographyN/A1 trial
Active Trials
NCT02540694Unknown350Est. Jun 2018
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
Inhaled TreprostinilPHASE_21 trial
Active Trials
NCT03814317Completed5Est. Dec 2025
Bristol Myers Squibb
1 program
CC-100004PHASE_2_31 trial
Active Trials
NCT00794274Completed15Est. Dec 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kite PharmaAmbrisentan
Bristol Myers SquibbCC-100004
United TherapeuticsInhaled Treprostinil
Enterprise Therapeutics19 gauge needle
Cook MedicalEndosonography

Clinical Trials (5)

Total enrollment: 536 patients across 5 trials

NCT00851929Kite PharmaAmbrisentan

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

Start: Nov 2008Est. completion: Nov 201116 patients
Phase 2/3Completed
NCT00794274Bristol Myers SquibbCC-100004

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

Start: Nov 2008Est. completion: Dec 201115 patients
Phase 2/3Completed
NCT03814317United TherapeuticsInhaled Treprostinil

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Start: Jan 2020Est. completion: Dec 20255 patients
Phase 2Completed
NCT04770948Enterprise Therapeutics19 gauge needle

An RCT of 19G EBUS-TBNA Needle in Suspected Sarcoidosis

Start: Mar 2021Est. completion: Sep 2023150 patients
N/ACompleted
NCT02540694Cook MedicalEndosonography

EBUS vs EUS-B for Diagnosing Sarcoidosis

Start: May 2015Est. completion: Jun 2018350 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.